Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy.
Serial IGF-1 levels in patients prior to and during adjuvant tamoxifen (TAM) treatment were followed in a retrospective study. Serum IGF-1 levels were determined by radioimmunoassay in 19 patients taking TAM and 19 controls, matched for age, body weight and other treatments. IGF-1 levels at 2 years were significantly lower in TAM patients (P < or = 0.05) compared to control patients. We observed a significant mean drop from pretreatment to treatment IGF-1 levels by 19.9% in the TAM group (P < or = 0.005), but also noted a mean 11.4% decline in the control group (P < or = 0.025). A subgroup analysis suggested that premenopausal were relatively resistant to the IGF-1 lowering effects of TAM as compared to postmenopausal women.
Friedl
A
A
Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison 53792.
Jordan
V C
VC
Pollak
M
M
D000328:Adult; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008593:Menopause; D008875:Middle Aged; D012189:Retrospective Studies; D013629:Tamoxifen / Q000627:therapeutic use*; D013997:Time Factors
D013629:Tamoxifen; D007334:Insulin-Like Growth Factor I